EI
GILD icon

Ethic Inc’s Gilead Sciences GILD Stock Holding History

Ethic Inc’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8M Buy
93,757
+7,959
+9% +$1.05M 0.15% 132
2026
Q1 		$12M Buy
85,798
+5,679
+7% +$795K 0.19% 108
2025
Q4 		$9.83M Buy
80,119
+3,103
+4% +$377K 0.15% 130
2025
Q3 		$8.55M Buy
77,016
+1,923
+3% +$219K 0.14% 151
2025
Q2 		$8.31M Buy
75,093
+3,821
+5% +$407K 0.15% 146
2025
Q1 		$7.93M Sell
71,272
-33,372
-32% -$3.44M 0.16% 134
2024
Q4 		$9.67M Buy
104,644
+7,638
+8% +$688K 0.2% 100
2024
Q3 		$7.11M Buy
97,006
+7,482
+8% +$571K 0.18% 120
2024
Q2 		$6.14M Sell
89,524
-7,482
-8% -$499K 0.14% 149
2024
Q1 		$7.11M Sell
97,006
-15,772
-14% -$1.21M 0.18% 120
2023
Q4 		$9.14M Buy
112,778
+4,423
+4% +$344K 0.27% 74
2023
Q3 		$8.12M Buy
108,355
+7,508
+7% +$577K 0.28% 72
2023
Q2 		$7.77M Buy
100,847
+5,808
+6% +$463K 0.29% 71
2023
Q1 		$7.89M Buy
95,039
+31,117
+49% +$2.58M 0.32% 62
2022
Q4 		$5.49M Buy
63,922
+19,028
+42% +$1.51M 0.3% 77
2022
Q3 		$2.77M Buy
44,894
+13,979
+45% +$881K 0.19% 133
2022
Q2 		$1.91M Buy
30,915
+3,895
+14% +$241K 0.13% 200
2022
Q1 		$1.61M Sell
27,020
-3,626
-12% -$232K 0.11% 240
2021
Q4 		$2.23M Sell
30,646
-12,477
-29% -$859K 0.17% 145
2021
Q3 		$3.01M Sell
43,123
-6,690
-13% -$470K 0.31% 75
2021
Q2 		$3.43M Buy
49,813
+15,969
+47% +$1.07M 0.42% 48
2021
Q1 		$2.19M Buy
33,844
+14,567
+76% +$939K 0.39% 53
2020
Q4 		$1.12M Buy
19,277
+4,419
+30% +$267K 0.3% 82
2020
Q3 		$939K Buy
14,858
+3,772
+34% +$262K 0.36% 63
2020
Q2 		$853K Buy
11,086
+1,446
+15% +$111K 0.49% 46
2020
Q1 		$721K Buy
9,640
+1,878
+24% +$130K 0.6% 46
2019
Q4 		$504K Buy
+7,762
New +$505K 0.37% 89

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ethic Inc's GILD Position: Q2 2026 in Review

Ethic Inc increased its Gilead Sciences (GILD) stake by 9.3% in Q2 2026, buying an estimated $1.05M and bringing the position to 93,757 shares worth $11.8M. The position accounts for 0.15% of the portfolio, ranked #132.

Ethic Inc first reported a position in GILD in Q4 2019 and has held it in 27 quarters since. The position peaked at $12M in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Ethic Inc held 93,757 shares of Gilead Sciences worth $11.8M as of Q2 2026.
  • Ethic Inc bought 7,959 Gilead Sciences shares in Q2 2026, an estimated $1.05M.
  • Gilead Sciences made up 0.15% of Ethic Inc's portfolio in Q2 2026, its #132 holding.
  • Ethic Inc first reported a position in Gilead Sciences in Q4 2019 and has held it in 27 quarters since.
  • Ethic Inc's Gilead Sciences position peaked at $12M in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.